These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 22833081)
1. Low-grade serous neoplasms of the ovary with transformation to high-grade carcinomas: a report of 3 cases. Garg K; Park KJ; Soslow RA Int J Gynecol Pathol; 2012 Sep; 31(5):423-8. PubMed ID: 22833081 [TBL] [Abstract][Full Text] [Related]
2. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A; Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818 [TBL] [Abstract][Full Text] [Related]
3. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Boyd C; McCluggage WG Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603 [TBL] [Abstract][Full Text] [Related]
4. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Dehari R; Kurman RJ; Logani S; Shih IeM Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266 [TBL] [Abstract][Full Text] [Related]
5. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
6. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma. Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420 [TBL] [Abstract][Full Text] [Related]
8. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma? Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721 [TBL] [Abstract][Full Text] [Related]
9. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Silva EG; Gershenson DM; Malpica A; Deavers M Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075 [TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of 103 ovarian serous and mucinous tumors. Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228 [TBL] [Abstract][Full Text] [Related]
11. Loss of p16INK4A expression in low-grade ovarian serous carcinomas. Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838 [TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas]. Shen XX; Yu L; Bi R; Yang WT Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression. Nilforoushan N; Moatamed NA Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902 [TBL] [Abstract][Full Text] [Related]
15. Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors. Zhang X; Devins K; Ko EM; Reyes MC; Simpkins F; Drapkin R; Schwartz LE; Yoon JY Gynecol Oncol; 2021 Jun; 161(3):762-768. PubMed ID: 33773808 [TBL] [Abstract][Full Text] [Related]
16. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714 [TBL] [Abstract][Full Text] [Related]
17. Grading ovarian serous carcinoma using a two-tier system. Malpica A; Deavers MT; Lu K; Bodurka DC; Atkinson EN; Gershenson DM; Silva EG Am J Surg Pathol; 2004 Apr; 28(4):496-504. PubMed ID: 15087669 [TBL] [Abstract][Full Text] [Related]
18. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases. Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817 [TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Singer G; Shih IeM; Truskinovsky A; Umudum H; Kurman RJ Int J Gynecol Pathol; 2003 Jan; 22(1):37-41. PubMed ID: 12496696 [TBL] [Abstract][Full Text] [Related]
20. Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases. Parker RL; Clement PB; Chercover DJ; Sornarajah T; Gilks CB Int J Gynecol Pathol; 2004 Jul; 23(3):265-72. PubMed ID: 15213603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]